Tonix Pharmaceuticals Holding Corp. (TNXP)
Tonix Pharmaceuticals Holding Corp. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Tonix Pharmaceuticals Holding Corp. (TNXP) is a Biotechnology company based in US with a market capitalization of $184.3M. Revenue grew 29.9% year-over-year and free cash flow was negative at -$103.2M. This page tracks TNXP's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 81 employees · IPO May 10, 2012
Valuation
Valuation & price
$15.74as of May 17, 2026· -74.4% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
0.75
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$184.3M
Market cap
29.9%
Revenue growth (YoY)
34.6%
Gross margin
-$103.2M
Free cash flow (USD)
-$206.3M
Net debt
Net cash position
276.0%
Share dilution
2/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2016 → 2025
Free cash flow by year
2016 → 2025
Gross margin by year
2023 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
0
Insider sells · 90 days
Earnings
Last report: 10-Q filed May 11, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- 8-K eventJul 21, 2026Filing
CMO Retirement
- 8-K eventJul 13, 2026Filing
Medicare Coverage Agreement
- 8-K eventJun 29, 2026Filing
Phase 2 Study Enrollment
- 8-K eventJun 8, 2026Filing
Commercial Coverage Agreement
- 8-K eventMay 27, 2026Filing
Clinical Study Publication
- 8-K eventMay 15, 2026Filing
New Drug Announcement
- Quarterly reportMay 11, 2026Filing
10-Q Filed
- 8-K eventMay 11, 2026Filing
Earnings Release
- 8-K eventMay 7, 2026Filing
Annual Meeting Results
- 8-K eventMay 6, 2026Filing
Commercial Payer Coverage Secured
Questions
Frequently asked questions
What is Tonix Pharmaceuticals Holding Corp.'s market cap?
Tonix Pharmaceuticals Holding Corp. (TNXP) has a market capitalization of $184.3M.
What is TNXP's P/E ratio?
A meaningful P/E ratio is not available for TNXP — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
What is TNXP's price-to-book (P/B) ratio?
TNXP trades at 0.75 times book value per share.
Are insiders buying TNXP stock?
SEC Form 4 filings show no open-market insider buys at Tonix Pharmaceuticals Holding Corp. in the last 90 days (0 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.